Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries

Published:2020-01 Issue: Volume:292 Page:178-187
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Ramaswami Uma,Futema Marta^ORCID,Bogsrud Martin P.,Holven Kirsten B.,Roeters van Lennep Jeanine,Wiegman Albert^ORCID,Descamps Olivier S.,Vrablik Michal^ORCID,Freiberger Tomas^ORCID,Dieplinger Hans^ORCID,Greber-Platzer Susanne,Hanauer-Mader Gabriele,Bourbon Mafalda,Drogari Euridiki,Humphries Steve E.^ORCID

Funder

International Atherosclerosis Society

British Heart Foundation

HEART UK

Cardiac Network Co-ordinating Group Wales

Royal College of Physicians

National Institute for Health Research University College London Hospitals Biomedical Research Centre

Fondation Leducq Transatlantic Networks of Excellence Program

Ministry of Health of the Czech Republic

Austrian Heart Foundation

Tyrolean Regional Government

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference38 articles.

1. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society;Nordestgaard;Eur. Heart J.,2013

2. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia;Marks;Atherosclerosis,2003

3. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis;Wald;BMJ,2007

4. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217;Benn;Eur. Heart J.,2016

5. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis;Akioyamen;BMJ Open,2017

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort;Archives de Pédiatrie;2024-04

2. Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia;JAMA Pediatrics;2024-03-01

3. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association;Circulation;2024-02-20

4. Efficacy and Safety of Statin Treatment in Children with Familial Hypercholesterolemia: Outcomes of 20 Years of Experience;Journal of Clinical Medicine;2023-11-21

5. Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment;European Journal of Preventive Cardiology;2023-10-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3